Efficacy and Safety of 5-Aminolevulinic Acid for Patients with Symptoms of Late-Onset Hypogonadism: A Preliminary Study.

Hiroki Koyasu Shigeo Horie Kazuhito Matsushita Takeshi Ashizawa Satoru Muto Shuji Isotani Tohru Tanaka Motowo Nakajima Akira Tsujimura

Published in: The world journal of men's health (2022)

The intake of 5-ALA for 8 weeks was beneficial for eugonadal patients with symptoms of LOH and no severe TEAEs was experienced. 5-ALA should be considered as an option for those patients.

Keyphrases

late onset
early onset
end stage renal disease
ejection fraction
newly diagnosed
photodynamic therapy
prognostic factors
peritoneal dialysis
sleep quality
patient reported outcomes
physical activity
drug induced